BMS-986497 (ORM-6151)
Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination With Azacitidine and in Triple Combination With Azacitidine and Venetoclax in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 105 patients (estimated)
- Sponsors
- Bristol Myers Squibb
- Tags
- GSPT1 Degrader, CD33
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1914
- NCT Identifier
- NCT06419634
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.